Biogen (BIIB) Equity Income (2012 - 2022)

Biogen (BIIB) has reported Equity Income for 8 consecutive years, with $3.4 million the latest figure, recorded in Q3 2022.

• In Q3 2022, Equity Income fell 92.44% year-over-year to $3.4 million; the TTM figure through Jun 2023 stood at $3.4 million (down 97.42% YoY), while the FY2022 annual figure was $2.6 million, down 92.55% from the prior year.
• Equity Income came in at $3.4 million for Q3 2022 at Biogen, down from $45.0 million in the prior quarter.
• The five-year high for Equity Income was $45.0 million in Q2 2021, with the low at -$28.7 million in Q1 2019.
• Average Equity Income over 4 years is $15.7 million, with a median of $25.9 million recorded in 2019.
• Across the five-year window, Equity Income soared 307.36% in 2020 and tumbled 92.44% in 2022, its largest moves.
• Year by year, Equity Income stood at $33.8 million in 2019, then plunged by 46.75% to $18.0 million in 2020, then jumped by 150.0% to $45.0 million in 2021, then sank by 92.44% to $3.4 million in 2022.
• According to Business Quant data, Equity Income over the past three periods registered $3.4 million, $45.0 million, and -$3.3 million for Q3 2022, Q2 2022, and Q1 2022 respectively.